1. Combination of pioglitazone, a PPARγ agonist, and synthetic surfactant B-YL prevents hyperoxia-induced lung injury in adult mice lung explants
- Author
-
Kurihara, Chie, Sakurai, Reiko, Chuang, Tsai-Der, Waring, Alan J, Walther, Frans J, and Rehan, Virender K
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lung ,Acute Respiratory Distress Syndrome ,Pediatric ,Neonatal Respiratory Distress ,Perinatal Period - Conditions Originating in Perinatal Period ,Rare Diseases ,Preterm ,Low Birth Weight and Health of the Newborn ,5.1 Pharmaceuticals ,Animals ,Mice ,Hyperoxia ,Lung Injury ,Pioglitazone ,PPAR gamma ,PPAR-gamma Agonists ,Surface-Active Agents ,Transforming Growth Factor beta ,Lung injury ,PPAR ? ,Surfactant ,PPARγ ,Pharmacology and Pharmaceutical Sciences ,Respiratory System ,Pharmacology and pharmaceutical sciences - Abstract
IntroductionHyperoxia-induced lung injury is characterized by acute alveolar injury, disrupted epithelial-mesenchymal signaling, oxidative stress, and surfactant dysfunction, yet currently, there is no effective treatment. Although a combination of aerosolized pioglitazone (PGZ) and a synthetic lung surfactant (B-YL peptide, a surfactant protein B mimic) prevents hyperoxia-induced neonatal rat lung injury, whether it is also effective in preventing hyperoxia-induced adult lung injury is unknown.MethodUsing adult mice lung explants, we characterize the effects of 24 and 72-h (h) exposure to hyperoxia on 1) perturbations in Wingless/Int (Wnt) and Transforming Growth Factor (TGF)-β signaling pathways, which are critical mediators of lung injury, 2) aberrations of lung homeostasis and injury repair pathways, and 3) whether these hyperoxia-induced aberrations can be blocked by concomitant treatment with PGZ and B-YL combination.ResultsOur study reveals that hyperoxia exposure to adult mouse lung explants causes activation of Wnt (upregulation of key Wnt signaling intermediates β-catenin and LEF-1) and TGF-β (upregulation of key TGF-β signaling intermediates TGF-β type I receptor (ALK5) and SMAD 3) signaling pathways accompanied by an upregulation of myogenic proteins (calponin and fibronectin) and inflammatory cytokines (IL-6, IL-1β, and TNFα), and alterations in key endothelial (VEGF-A and its receptor FLT-1, and PECAM-1) markers. All of these changes were largely mitigated by the PGZ + B-YL combination.ConclusionThe effectiveness of the PGZ + B-YL combination in blocking hyperoxia-induced adult mice lung injury ex-vivo is promising to be an effective therapeutic approach for adult lung injury in vivo.
- Published
- 2023